These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25985046)

  • 21. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD.
    Farabaugh A; Mischoulon D; Schwartz F; Pender M; Fava M; Alpert J
    Depress Anxiety; 2007; 24(6):433-9. PubMed ID: 17086540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
    Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T; Harley R; Papakostas GI; Montoya HD; Fava M; Alpert JE
    Psychol Med; 2004 Apr; 34(3):555-61. PubMed ID: 15259840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression.
    Vittengl JR; Clark LA; Jarrett RB
    J Affect Disord; 2009 Jan; 112(1-3):135-43. PubMed ID: 18539337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
    Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
    Gelenberg AJ; Trivedi MH; Rush AJ; Thase ME; Howland R; Klein DN; Kornstein SG; Dunner DL; Markowitz JC; Hirschfeld RM; Keitner GI; Zajecka J; Kocsis JH; Russell JM; Miller I; Manber R; Arnow B; Rothbaum B; Munsaka M; Banks P; Borian FE; Keller MB
    Biol Psychiatry; 2003 Oct; 54(8):806-17. PubMed ID: 14550680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How much cognitive therapy, for which patients, will prevent depressive relapse?
    Jarrett RB; Vittengl JR; Clark LA
    J Affect Disord; 2008 Dec; 111(2-3):185-92. PubMed ID: 18358541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing relapse in depressed outpatients with atypical features: a pilot study.
    Jarrett RB; Kraft D; Schaffer M; Witt-Browder A; Risser R; Atkins DH; Doyle J
    Psychother Psychosom; 2000; 69(5):232-9. PubMed ID: 10965287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovery and recurrence following treatment for adolescent major depression.
    Curry J; Silva S; Rohde P; Ginsburg G; Kratochvil C; Simons A; Kirchner J; May D; Kennard B; Mayes T; Feeny N; Albano AM; Lavanier S; Reinecke M; Jacobs R; Becker-Weidman E; Weller E; Emslie G; Walkup J; Kastelic E; Burns B; Wells K; March J
    Arch Gen Psychiatry; 2011 Mar; 68(3):263-9. PubMed ID: 21041606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
    Rush AJ; Wisniewski SR; Zisook S; Fava M; Sung SC; Haley CL; Chan HN; Gilmer WS; Warden D; Nierenberg AA; Balasubramani GK; Gaynes BN; Trivedi MH; Hollon SD
    Psychol Med; 2012 Jun; 42(6):1131-49. PubMed ID: 22008447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?
    Taylor DJ; Walters HM; Vittengl JR; Krebaum S; Jarrett RB
    J Affect Disord; 2010 Jun; 123(1-3):181-7. PubMed ID: 19733912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study.
    Bockting CL; Spinhoven P; Wouters LF; Koeter MW; Schene AH;
    J Clin Psychiatry; 2009 Dec; 70(12):1621-8. PubMed ID: 20141705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence.
    Bockting CL; Hollon SD; Jarrett RB; Kuyken W; Dobson K
    Clin Psychol Rev; 2015 Nov; 41():16-26. PubMed ID: 25754289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.